AI is rewriting biotech’s commercial playbook—cutting waste, shrinking teams, and giving first‑time drugmakers a faster, smarter path to launch.

Gilead has penned a potential $1.5 billion synthetic lethality deal with a Chinese biotech. A cell therapy company could end ...

Despite a wave of AI-fueled layoffs, the pharma and biotech industries could be spared from massive cutbacks for now.

Real-Time Compliance Tracking, FDA Inspection Data, and Proactive Risk Management for Life Sciences Quality Teams ...

As President Trump hails pricing agreements with the pharmaceutical industry, some biotech companies are worried they have ...

Conestoga Capital Advisors, an asset management company, released its fourth-quarter 2025 investor letter. A copy of the ...

The pharmaceutical service provider Vetter has confirmed its plans to build a state-of-the-art production facility in ...

Over the past two calendar years, acquirers have agreed to pay more than $38 billion to purchase venture-backed companies in ...

The market expects Collegium Pharmaceutical (COLL) to deliver a year-over-year increase in earnings on higher revenues when ...

The Evolving Landscape of Pharmaceutical Wastewater Management The global pharmaceutical industry is currently navigating a period of significant transition, where environmental compliance has moved ...

India has sought stronger cooperation with Switzerland in research and development, biotechnology and pharmaceuticals to ...

In a country where academic qualifications are often regarded as a lifelong compass, his journey defies convention.